Femasys Strikes SandsRx Pharmacy Deal to Support FemaSeed Fertility Launch; FEMY Shares Rise 4.29%

Femasys Inc. (FEMY) announced an agreement with SandsRx Pharmacy to coordinate medications and patient support for the commercial launch of its FemaSeed fertility portfolio to OB/GYN practices. Shares of the biomedical company rose 4.29% to $1.70 following the news. The partnership is the first in a planned network of specialty pharmacy collaborations. SandsRx will provide medication expertise, insurance verification, financial assistance, pharmacist consultations, virtual nurse support and coordinated delivery. FemaSeed is an in-office treatment that places sperm directly into the fallopian tube. The fertility portfolio also includes FemVue, SpermVue and FemSperm, designed to let OB/GYN practices offer earlier, lower-cost fertility care without referrals to specialists or outside labs. Femasys is also advancing its non-surgical permanent birth control solution FemBloc through the ongoing FINALE pivotal trial toward FDA approval, following regulatory clearances in Europe, the UK and New Zealand in 2025. FEMY has traded between $1.46 and $22.20 over the past year.